AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 175 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,348,623 | -83.9% | 73,655 | -81.0% | 0.26% | -81.1% |
Q2 2023 | $8,354,277 | +17.5% | 387,310 | +59.8% | 1.39% | +1.9% |
Q1 2023 | $7,112,016 | +21.9% | 242,400 | +53.5% | 1.37% | +21.1% |
Q4 2022 | $5,836,253 | +0.9% | 157,950 | -23.1% | 1.13% | -0.9% |
Q3 2022 | $5,782,000 | – | 205,400 | – | 1.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |